• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Pardes Biosciences to Present at SVB Securities Global Biopharma Conference

    2/1/23 8:30:00 AM ET
    $PRDS
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PRDS alert in real time by email

    CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of COVID-19, announced that management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 10:40 a.m. PT / 1:40 p.m. ET.

    A live audio webcast of the fireside chat will be available in the Investors section of Pardes' website at www.pardesbio.com, with an archived replay available for 30 days following the event.

    About Pardes Biosciences, Inc.

    Pardes Biosciences is a clinical-stage biopharmaceutical company created to help solve pandemic-sized problems, starting with COVID-19. We are dedicated to discovering and developing potent and easy-to-prescribe oral antiviral drug candidates so that patients everywhere can get well sooner. For more information, please visit www.pardesbio.com.

    Availability of Other Information about Pardes Biosciences

    Pardes Biosciences intends to use the Investors page of its website (https://ir.pardesbio.com) as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Pardes Biosciences' Investors website, in addition to following Pardes Biosciences' press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.

    Investor Contacts:

    Patrick O'Brien

    [email protected]

    Stephen Jasper

    Gilmartin Group

    (858) 525-2047

    [email protected]



    Primary Logo

    Get the next $PRDS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRDS

    DatePrice TargetRatingAnalyst
    7/18/2023Mkt Outperform → Mkt Perform
    JMP Securities
    3/15/2022Outperform
    SVB Leerink
    1/18/2022$25.00Buy
    Jefferies
    More analyst ratings

    $PRDS
    SEC Filings

    See more
    • SEC Form 15-12G filed by Pardes Biosciences Inc.

      15-12G - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

      9/11/23 8:00:13 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Pardes Biosciences Inc.

      EFFECT - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

      9/1/23 12:15:04 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Pardes Biosciences Inc.

      EFFECT - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

      9/1/23 12:15:24 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care